IL291791B2 - Methods for treating sleep timing disorders - Google Patents

Methods for treating sleep timing disorders

Info

Publication number
IL291791B2
IL291791B2 IL291791A IL29179122A IL291791B2 IL 291791 B2 IL291791 B2 IL 291791B2 IL 291791 A IL291791 A IL 291791A IL 29179122 A IL29179122 A IL 29179122A IL 291791 B2 IL291791 B2 IL 291791B2
Authority
IL
Israel
Prior art keywords
compound
pharmaceutically acceptable
solvate
acceptable salt
use according
Prior art date
Application number
IL291791A
Other languages
English (en)
Hebrew (he)
Other versions
IL291791B1 (en
IL291791A (en
Original Assignee
Eisai R&D Man Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eisai R&D Man Co Ltd filed Critical Eisai R&D Man Co Ltd
Publication of IL291791A publication Critical patent/IL291791A/en
Publication of IL291791B1 publication Critical patent/IL291791B1/en
Publication of IL291791B2 publication Critical patent/IL291791B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Dermatology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
IL291791A 2016-05-12 2017-05-11 Methods for treating sleep timing disorders IL291791B2 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201662335611P 2016-05-12 2016-05-12
US201662335599P 2016-05-12 2016-05-12
US201662413976P 2016-10-27 2016-10-27
US201662414599P 2016-10-28 2016-10-28
US201662414606P 2016-10-28 2016-10-28
PCT/US2017/032228 WO2017197160A1 (en) 2016-05-12 2017-05-11 Methods of treating circadian rhythm sleep disorders

Publications (3)

Publication Number Publication Date
IL291791A IL291791A (en) 2022-06-01
IL291791B1 IL291791B1 (en) 2025-05-01
IL291791B2 true IL291791B2 (en) 2025-09-01

Family

ID=58745465

Family Applications (2)

Application Number Title Priority Date Filing Date
IL291791A IL291791B2 (en) 2016-05-12 2017-05-11 Methods for treating sleep timing disorders
IL262803A IL262803B (en) 2016-05-12 2018-11-06 Methods of treating circadian rhythm sleep disorders

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL262803A IL262803B (en) 2016-05-12 2018-11-06 Methods of treating circadian rhythm sleep disorders

Country Status (16)

Country Link
US (2) US11096941B2 (OSRAM)
EP (2) EP3454859B1 (OSRAM)
JP (2) JP6888026B2 (OSRAM)
KR (2) KR102511855B1 (OSRAM)
CN (1) CN109640998A (OSRAM)
AU (3) AU2017264871B2 (OSRAM)
CA (1) CA3022068A1 (OSRAM)
ES (1) ES2904625T3 (OSRAM)
IL (2) IL291791B2 (OSRAM)
MX (1) MX379318B (OSRAM)
MY (1) MY199382A (OSRAM)
RU (1) RU2763493C2 (OSRAM)
SG (1) SG11201809527UA (OSRAM)
TW (1) TWI795359B (OSRAM)
WO (1) WO2017197160A1 (OSRAM)
ZA (1) ZA201807903B (OSRAM)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL291791B2 (en) * 2016-05-12 2025-09-01 Eisai R&D Man Co Ltd Methods for treating sleep timing disorders
JP2022538170A (ja) * 2019-06-26 2022-08-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 睡眠問題の治療のためのレンボレキサント
CN114096251A (zh) * 2019-06-26 2022-02-25 卫材R&D管理有限公司 用于治疗睡眠问题的莱博雷生
WO2020263253A1 (en) * 2019-06-26 2020-12-30 Moline Margaret Lemborexant for treating sleep issues
CN114502167A (zh) * 2019-09-13 2022-05-13 卫材R&D管理有限公司 用于治疗失眠的药物组合物
US20240010629A1 (en) * 2019-12-11 2024-01-11 Teva Czech Industries S.R.O Solid state form of lemborexant
IL294033A (en) * 2020-01-16 2022-08-01 Eisai R&D Man Co Ltd Drug substance of lemborexant and medicinal composition comprising same
CN111450076A (zh) * 2020-05-25 2020-07-28 安徽省逸欣铭医药科技有限公司 一种Lemborexant软胶囊组合物及其制备方法
CN114159568B (zh) * 2020-09-11 2025-08-01 北京原基华毅生物科技有限公司 Sik抑制剂在制备用于预防和/或治疗睡眠障碍的药物中的应用
WO2023007320A1 (en) * 2021-07-26 2023-02-02 Eisai R&D Mangement Co., Ltd. Lemborexant for use in methods of treating irregular sleep-wake rhythm disorder and circadian rhythm sleep disorders associated with neurodegenerative diseases
CN116421605B (zh) * 2022-01-04 2024-08-02 中国科学院脑科学与智能技术卓越创新中心 Isx-9在治疗衰老相关的昼夜节律幅度下降和睡眠障碍方面的应用
AU2023347307A1 (en) * 2022-09-23 2025-03-13 Eisai R&D Management Co., Ltd. Methods of reducing neurodegeneration associated with neurodegenerative diseases

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016063995A1 (en) * 2014-10-23 2016-04-28 Eisai R&D Management Co., Ltd. Compositions and methods for treating insomnia

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2005082143A1 (en) * 2004-02-20 2005-09-09 Lifescape Biosciences Incorporated Compositions and methods for sleep regulation
ATE458740T1 (de) * 2006-08-28 2010-03-15 Actelion Pharmaceuticals Ltd 1,4,5,6,7,8-hexahydro-1,2,5-triaza-azulen- derivate als orexinrezeptor-antagonisten
RS54101B1 (sr) 2010-09-22 2015-10-30 Eisai R&D Management Co. Ltd. Ciklopropansko jedinjenje
JP6346862B2 (ja) * 2012-02-07 2018-06-20 エオラス セラピューティクス， インコーポレイテッド オレキシンレセプターアンタゴニストとしての置換プロリン／ピペリジン
IL291791B2 (en) * 2016-05-12 2025-09-01 Eisai R&D Man Co Ltd Methods for treating sleep timing disorders

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016063995A1 (en) * 2014-10-23 2016-04-28 Eisai R&D Management Co., Ltd. Compositions and methods for treating insomnia

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
BOSS, CHRISTOPH, ET AL.:, RECENT TRENDS IN OREXIN RESEARCH—2010 TO 2015., 15 May 2015 (2015-05-15) *
MUSIEK, ERIK S ET AL., SLEEP, CIRCADIAN RHYTHMS, AND THE PATHOGENESIS OF ALZHEIMER DISEASE, 13 March 2015 (2015-03-13) *
YOSHIDA, YU, ET AL.:, DISCOVERY OF (1 R, 2 S)-2-{[(2, 4-DIMETHYLPYRIMIDIN-5-YL) OXY] METHYL}-2-(3-FLUOROPHENYL)-N-(5-FLUOROPYRIDIN-2-YL) CYCLOPROPANECARBOXAMIDE (E2006): A POTENT AND EFFICACIOUS ORAL OREXIN RECEPTOR ANTAGONIST, 11 June 2015 (2015-06-11) *

Also Published As

Publication number Publication date
NZ748555A (en) 2025-06-27
IL291791B1 (en) 2025-05-01
CN109640998A (zh) 2019-04-16
AU2025205336A1 (en) 2025-07-31
JP2019518732A (ja) 2019-07-04
JP2021120410A (ja) 2021-08-19
RU2018143809A (ru) 2020-06-15
EP3454859B1 (en) 2021-12-01
SG11201809527UA (en) 2018-11-29
JP6888026B2 (ja) 2021-06-16
IL262803A (en) 2018-12-31
KR102511855B1 (ko) 2023-03-20
EP4056180A1 (en) 2022-09-14
AU2017264871A1 (en) 2018-11-15
MX379318B (es) 2025-03-10
BR112018073037A2 (pt) 2019-02-26
MX2018013663A (es) 2019-07-18
WO2017197160A1 (en) 2017-11-16
AU2017264871B2 (en) 2023-03-16
TWI795359B (zh) 2023-03-11
US20210353625A1 (en) 2021-11-18
EP3454859A1 (en) 2019-03-20
CA3022068A1 (en) 2017-11-16
KR20190013820A (ko) 2019-02-11
IL262803B (en) 2022-05-01
AU2023203418A1 (en) 2023-06-29
US20200179382A1 (en) 2020-06-11
RU2018143809A3 (OSRAM) 2020-09-17
ZA201807903B (en) 2021-04-28
JP7150096B2 (ja) 2022-10-07
KR20230043227A (ko) 2023-03-30
TW201740952A (zh) 2017-12-01
MY199382A (en) 2023-10-25
RU2763493C2 (ru) 2021-12-29
ES2904625T3 (es) 2022-04-05
US11096941B2 (en) 2021-08-24
IL291791A (en) 2022-06-01

Similar Documents

Publication Publication Date Title
IL291791B1 (en) Methods for treating sleep timing disorders
JP2019518732A5 (OSRAM)
Nesbitt et al. Cluster headache
Ang et al. Absent sleep EEG spindle activity in GluA1 (Gria1) knockout mice: relevance to neuropsychiatric disorders
Adamchic et al. Acute effects and after-effects of acoustic coordinated reset neuromodulation in patients with chronic subjective tinnitus
JP2020528075A5 (OSRAM)
RU2680247C2 (ru) Средство, усиливающее эффект реабилитации после нервного повреждения, которое содержит производное простого алкилового эфира или его соль
PH12021553232A1 (en) 2h-indazole derivatives and their use in the treatment of disease
Bennett et al. Therapeutic hypothermia for status epilepticus: a report, historical perspective, and review
Carano et al. Glycopyrrolate and theophylline for the treatment of severe pallid breath-holding spells
WO2023108170A3 (en) Systems, devices, and methods for enhancing the neuroprotective effects of non-invasive gamma stimulation with pharmacological agents
ATE482711T1 (de) Kombinationsprodukt mit einem antagonisten oder inversen agonisten von histamine-rezeptor h3 und einem antipsychotischen oder antidepressiven mittel, und ihre verwendung zur herstellung eines medikaments zur verhinderung der nachteiligen wirkungen von psychotropika
Bhat et al. Increasing off-time improves sleep-disordered breathing induced by vagal nerve stimulation
PH12022552763A1 (en) Medical use of daridorexant
NZ748555B2 (en) Methods of treating circadian rhythm sleep disorders
Roth et al. Effects of medial thalamotomy and pallido-thalamic tractotomy on sleep and waking EEG in pain and Parkinsonian patients
MX2020012912A (es) Método de tratamiento con el agonista inverso del receptor de histamina-3.
Fantini et al. Idiopathic rapid eye movement sleep behaviour disorder
Khachatryan et al. Sleep-onset central apneas as triggers of severe nocturnal seizures
Peyvandi et al. Comparison of peritonsillar infiltration of lidocaine and bupivacaine for management of postoperative pain of tonsillectomy
Millichap et al. Controlled evaluation of primidone and diphenylhydantoin sodium: comparative anticonvulsant efficacy and toxicity in children
Langenbruch et al. P138. Acute onset and reversibility of triphasic waves in the EEG correlating with hypercapnia
Pedrera-Mazarro et al. Nocturnal panic attacks
Kanzaki et al. The damped pendular rotation test in central vestibular disorders
Deak Sleep and neurological disorders